WithdrawnPhase 2Phase 3ACTRN12605000153617
The role of Dipyridamole in Improving the False Negative Rate in Pre-Operative Parathyroid Adenoma Localisation Using 99mTc Sestamibi
Sponsor
Robert Williams
Enrollment
20 participants
Start Date
Dec 11, 2005
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying the The role of Dipyridamole in Improving the False Negative Rate in Pre-Operative Parathyroid Adenoma Localisation Using 99mTc Sestamibi. You may be eligible if you are aged 18 or older. Participation likely involves medical imaging, a surgical procedure.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The use of Dipyridamole in Improving the False Negative Rate in Pre-Operative Parathyroid Adenoma Localisation Using 99mTc Sestamibi.
Dipyridamole is used to enhance the uptake of Tc99m-Sestamibi in
The use of Dipyridamole in Improving the False Negative Rate in Pre-Operative Parathyroid Adenoma Localisation Using 99mTc Sestamibi. Dipyridamole is used to enhance the uptake of Tc99m-Sestamibi in repeat parathyroid imaging.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000153617